http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2326690-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e488341cd57d4500b986ed6b51cdf096 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2000-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2d65137a05f682fadfbda6456b8abd4 |
| publicationDate | 2000-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2326690-A1 |
| titleOfInvention | The process for manufacturing topical ophthalmic preparations without systemic effects |
| abstract | For treating eye diseases, various kinds of medications are used. They are used in form of topical preparations or in form of systemic preparations to be taken orally or parenterally. Of topical preparations some are for topical use only e.g. framycetin, neomycin, loteprednol ebanoate, etc. However, large majority of topical ophthalmic drugs are for systemic use also, e.g.. Ciprofloxacin, Gentamicin, Timolol, Clonidine, Dexamethasone, Betamethasone, Carbachol, etc. Some of these drugs when used topically are also found to have systemic effects and if they are of serious nature limits the use of that drug, e.g. cardiopulmonary effects of B-blockers like timolol. Dryness of mouth, flush, fever, tachy cardia, urinary retention, convulsion irritability with atropine. Hypertension with phenylephine. Increased salivation, nausea, vomiting, diarrhea, stomach cramps, bronchial secretions, bronchial constriction, asthma, bradycardia, paresthesia with miotics, Hypotension with clonidine. Dry mouth, fatigue and drowsiness with apraclonidine and brimonidine. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2481412-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011061252-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2815748-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013001073-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2388007-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2329849-A1 |
| priorityDate | 1999-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.